Healthcare Value Capital’s Albany Molecular Research Inc AMRI Stock Holding History

Healthcare Value Capital’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-50,000	Closed	-$672K	–	26
2016 Q2	$672K	Hold	50,000	–	–	0.81%	18
2016 Q1	$765K	Buy	+50,000	New	+$784K	1.12%	17
2015 Q2	–	Sell	-120,000	Closed	-$2.11M	–	40
2015 Q1	$2.11M	Hold	120,000	–	–	2.3%	16
2014 Q4	$1.95M	Buy	+120,000	New	+$2.2M	3.57%	9
2014 Q3	–	Sell	-100,000	Closed	-$2.01M	–	44
2014 Q2	$2.01M	Hold	100,000	–	–	1.69%	16
2014 Q1	$1.86M	Buy	+100,000	New	+$1.38M	1.22%	23

Other funds holding AMRI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Healthcare Value Capital's AMRI Position: Q2 2017 in Review

Healthcare Value Capital sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 302,400 shares — an estimated $4.24M sold.

Healthcare Value Capital first reported a position in AMRI in Q1 2014 and held it in 13 quarters. The position peaked at $11.5M in Q2 2015. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Healthcare Value Capital reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Healthcare Value Capital sold 302,400 Albany Molecular Research Inc shares in Q2 2017, an estimated $4.24M.
Healthcare Value Capital first reported a position in Albany Molecular Research Inc in Q1 2014 and held it in 13 quarters.
Healthcare Value Capital's Albany Molecular Research Inc position peaked at $11.5M in Q2 2015.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Healthcare Value Capital's 13F filing for Q2 2017, filed 10 Aug 2017.